Back to News
Market Impact: 0.1
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
Source: globenewswire.com
Healthcare & BiotechPrivate Markets & VentureCompany Fundamentals
Psyence Biomedical announced that both milestones attached to its backstop subscription commitment in subsidiary Psyence Labs Ltd. The provided article text does not specify the milestones, commitment amount, or their outcome.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- The U.S. market has never been more focused on one single bet—but AI’s payoff will likely take decades
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Why is Tesla stock falling after-hours today?
- Zuckerberg told Meta directors he might leave California, where he could lose billions to a wealth tax. Meta answered with a new class of stock
- CoreWeave’s market confidence erodes as bond yields spike and stock sinks
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template